Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,612 GBX | -8.76% | -6.90% | +11.71% |
04:19pm | GSK’s Rectal Cancer Drug Shows 100% Complete Response Rate in Longer-term Phase 2 Trial | MT |
03:28pm | Trending : GSK Shares Tumble on Zantac's Legal Setback | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.71% | 91.66B | |
+42.08% | 739B | |
+32.89% | 598B | |
-5.25% | 353B | |
+17.82% | 318B | |
+5.10% | 285B | |
+16.60% | 240B | |
+9.52% | 210B | |
-5.19% | 206B | |
+7.93% | 164B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GSK Faces Whistleblower Lawsuit for Allegedly Hiding Antacid Zantac's Cancer Risks